Results 261 to 270 of about 2,254,748 (322)

Improving the Capstone Biochemistry Lab and Evolution to a Course-Based Undergraduate Research Experience: Lessons Learned from the COVID-19 Online Modality. [PDF]

J Coll Sci Teach
Rascón AA.
europepmc   +1 more source

Textbook of Biochemistry

, 1943
NULL AUTHOR_ID
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

VitroBert: modeling DILI by pretraining BERT on in vitro data. [PDF]

J Cheminform
Masood MA, Nagaraja AA, Belaid K, Mesens N, Ceulemans H, Kaski S, Herman D, Heinonen M.   +7 more
europepmc   +1 more source

Fundamentals of Biochemistry with Laboratory Experiments

, 1938
Carl L. A. Schmidt, Frank Worthington Allen   +1 more
openalex   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Correction: Structural insights into the Caprin-2 HR1 domain in canonical Wnt signaling. [PDF]

J Biol Chem
Su C, Zhong Y, Zhou Z, Li Y, Jia Y, Xie S, Zhao J, Miao H, Luo H, Li Z, Shi Z, Li L, Song X.   +12 more
europepmc   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Correction: Pandey et al. Enhancing the Conformational Stability of the cl-Par-4 Tumor Suppressor via Site-Directed Mutagenesis. <i>Biomolecules</i> 2023, <i>13</i>, 667. [PDF]

Biomolecules
Pandey S, Raut KK, Baudin A, Djemri L, Libich DS, Ponniah K, Pascal SM.   +6 more
europepmc   +1 more source